Engineered extracellular vesicles (sEV) bearing miR-654-5p effectively delivers miR-654-5p to HCC cells to increase sorafenib-induced ferroptosis by inhibiting HSPB1 in sorafenib-resistant HCC cells and xenograft tumors, restoring their sensitivity to sorafenib [173]. The gene discussed is HSPB1; the disease is hepatocellular carcinoma.